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 10 
Abstract 11 
 12 
Epigenetic reprogramming is a cancer hallmark but how it unfolds during early neoplastic 13 
events and its role in carcinogenesis and cancer progression is not fully understood. Here 14 
we show that resetting from primed to naïve human pluripotency results in acquisition of a 15 
DNA methylation landscape mirroring the cancer DNA methylome, with gradual 16 
hypermethylation of bivalent developmental genes. We identify a dichotomy between 17 
bivalent genes that do and do not become hypermethylated, which is also mirrored in 18 
cancer. We find that loss of H3K4me3 at bivalent regions is associated with gain of 19 
methylation. Additionally, we observe that promoter CpG island hypermethylation is not 20 
restricted solely to emerging naïve cells, suggesting that it is a feature of a heterogeneous 21 
intermediate population during resetting. These results indicate that transition to naïve 22 
pluripotency and oncogenic transformation share common epigenetic trajectories, which 23 
implicates reprogramming and the pluripotency network as a central hub in cancer 24 
formation. 25 
 26 
Introduction 27 
 28 
Disruption of DNA methylation patterns is a hallmark of human cancers, typically 29 
characterised by loss of global genomic DNA methylation accompanied by site-specific 30 
hypermethylation1-4. DNA hypomethylation is typically associated with genomic 31 
instability5,6, while site-specific DNA hypermethylation occurs at promoter CpG islands 32 
(CGIs) and can be associated with repression of tumour suppressor genes in cancer cells7,8. 33 
The majority of these observations have been made in cancer cell lines or primary cancer 34 
cells, but they are not fully representative of the processes occurring during the transition of 35 
normal cells into malignant cells. The underlying mechanisms that give rise to these 36 
opposing patterns of genomic DNA methylation in early stages of human cancer 37 
development remain elusive, as does the timing and biological function of such events in 38 
cancer initiation and progression. To this end, a recent study demonstrated that ageing and 39 
cancer associated DNA hypermethylation accelerates cellular transformation in a BrafV600E 40 
mouse colon organoid system, through suppression of Wnt signalling regulators in a 41 
progressive manner9. This study functionally links promoter CGI hypermethylation with 42 
oncogenic transformation, demonstrating a causal relationship. Nevertheless, how de novo 43 
DNA methyltransferase activity is preferentially targeted to specific regions of the genome 44 
in the context of aberrant cancer methylation remains largely a mystery.  45 
It has been hypothesised that cancer cells follow an evolutionary trajectory towards a stem 46 
cell state, which allows both self-renewal and differentiation10, and more recently, cancer-47 
related mutations have been identified in naive human embryonic stem cells (hESCs)11.  48 
 49 
Here we identify cancer-like DNA methylation changes during primed to naïve hESC 50 
resetting using the recently developed NANOG/KLF2 overexpression + 2iLGö method 51 
(comprising two small-molecule inhibitors of MEK and GSK3β, human recombinant 52 
leukaemia inhibitory factor, and a pan-PKC inhibitor)12. Our system provides a unique 53 
opportunity to investigate the mechanism of DNA hypermethylation in human cells in a 54 
temporal manner, and sheds light on the role of the transcription factor and pluripotency 55 
networks in driving cancer-like DNA hypermethylation.  56 
 57 
Results 58 
 59 
Naïve resetting induces CGI promoter hypermethylation 60 
 61 
To investigate the kinetics of the changing DNA methylation landscape between primed and 62 
naïve hESCs, we transitioned primed hESCs to the naïve state as previously described12, by 63 
inducing NANOG/KLF2 transgenes with doxycycline. We also captured the two intermediary 64 
states, termed ‘early transition’ and ‘late transition’ when the cells are in 2iL+dox or 2iL+Gö, 65 
respectively (Fig. 1a). We see global DNA demethylation of the genome in naïve cells as 66 
reported previously12, measured by the Infinium MethylationEPIC array and mass 67 
spectrometry (Supplementary Figs 1a-1c). The loss of 5-methylcytosine (5mC) is gradual and 68 
is accompanied by the loss of its oxidation product, 5-hydroxymethylcytosine (5hmC) 69 
(Supplementary Fig. 1a). Interestingly, while the majority of the genome is demethylated, 70 
we observe hypermethylation of a subset of CpGs (an increase of >10% methylation 71 
compared to primed hESCs), exemplified by the HOXA cluster (Figs 1b, 1c, Supplementary 72 
Fig. 1d). This gain in methylation is evident as cells go through the early transition of 73 
resetting, with a peak of hypermethylated CpGs as the cells go through the late transition of 74 
resetting (Figs 1b, 1c). Although the peak of hypermethylation coincides with the cells being 75 
transitioned into 2iL+ Gö conditions, the abundance of hypermethylation is independent of 76 
the addition of Gö (Supplementary Fig. 1e), indicating a time-dependent accrual of DNA 77 
methylation instead. As the cells stabilise in the naïve state, we observe maintenance of a 78 
proportion of hypermethylated sites, while some CpGs show only a transient gain in 79 
methylation (Fig. 1b). The reproducibility of the hypermethylation during the resetting 80 
process is apparent from the strong overlap between hypermethylated sites across 81 
biologically independent MethylationEPIC arrays (with 2 or 3 cell populations assayed within 82 
each array) and when compared to published whole genome bisulfite sequencing (WGBS) 83 
data, suggesting that the site-specific gain in methylation is not random, and likely has a 84 
biological function (Supplementary Figs 1f, 1g). Moreover, as primed hESCs and hESCs 85 
during the early transition of resetting proliferate and cycle at comparable rates as 86 
measured by loss of bromodeoxyuridine (BrdU), the site-specific gain in methylation upon 87 
resetting is the result of an active process rather than the selection of an existing 88 
subpopulation of cells (Supplementary Fig 1h). 89 
 90 
We next sought to investigate the genomic context with which hypermethylation occurs. 91 
We utilised the Encyclopaedia of DNA elements (ENCODE) ChIP-seq datasets for the H1 92 
primed hESC cell line and overlapped them with resetting-associated hypermethylated 93 
probes. We observed that hypermethylated probes are enriched within regions marked by 94 
H3K4me1/2/3 and H3K27me3 in primed hESCs (Fig. 1d). The majority of these fall within 95 
regions marked by bivalent histone modifications, defined by co-occurrence of H3K4me3 96 
and H3K27me3 (Fig. 1e). Bivalency typically marks regulatory regions (promoters and 97 
enhancers with overlapping transcription factor binding sites)13, and as expected, we saw a 98 
striking overlap with CGIs and regulatory regions, which is not the case for hypomethylated 99 
probes (Figs 1f, 1g). In addition, the majority of the hypermethylated probes reside within 100 
ChromHMM predicted poised promoters (Fig. 1h). To validate our results, we also re-101 
analysed published whole-genome bisulfite sequencing data for primed and naïve hESCs12, 102 
and identified 26,625 regions (300bp each) that were hypermethylated (>10% increase in 103 
naïve vs primed) in naïve hESCs. In agreement with our Illumina MethylationEPIC array data, 104 
we observed enrichment of these regions within loci marked by bivalency in primed hESCs, 105 
with a bias towards regulatory regions and CGIs (Supplementary Figs 2a-2e). This strongly 106 
reinforces the highly reproducible nature of the DNA hypermethylation that occurs upon 107 
resetting of primed hESCs to naïve pluripotency. 108 
 109 
To eliminate the possibility that the hypermethylation is simply an artefact of the 110 
NANOG/KLF2 + 2iLGö in vitro resetting system, we compared 2iLGö naïve hypermethylated 111 
regions to hypermethylated regions identified in naïve cells generated using the alternative 112 
methods of naïve hESC generation and those in the human inner cell mass (ICM)14-17. We 113 
saw a significant overlap between the hypermethylated regions in each of these data sets 114 
compared to the 2iLGö naïve cells, in both cases also enriched within H3K4me1/2/3 and 115 
H3K27me3 regions in primed hESCs (Supplementary Figs 3a-3g). Interestingly, we do not 116 
detect any hypermethylation in mouse embryonic stem cells cultured in 2i compared to 117 
those cultured in serum18, and the hypermethylation present in the mouse ICM19 is far less 118 
extensive and does not enrich at bivalent regions (Supplementary Figs 3h-3j). Overall from 119 
these results, we can conclude that the hypermethylation pattern is a feature of in vitro 120 
naïve human pluripotency and recapitulates the in vivo relationship between the ICM and 121 
the post-implantation embryo.  122 
 123 
Developmental genes are hypermethylated and repressed 124 
 125 
To identify the genes targeted by hypermethylation, we performed gene ontology (GO) 126 
analysis of the genes and classified a gene as hypermethylated if it possessed a 127 
hypermethylated probe/ region within 1500bp upstream of its transcription start site (TSS). 128 
GO analysis revealed an extensive enrichment of hypermethylated genes in developmental 129 
pathways, particularly neuronal development, while hypomethylated genes show much 130 
weaker enrichment in pathways involved in cell cycle and metabolism (Fig. 2a, 131 
Supplementary Fig. 4a). To investigate whether hypermethylation is associated with gene 132 
silencing, we performed temporal transcriptome analysis of cells during the transition from 133 
primed to naïve pluripotency and observed thousands of genes differentially expressed at 134 
each stage of the transition compared to primed hESCs, with an enrichment of 135 
downregulated genes in developmental pathways (Supplementary Figs 4b, 4c).  We 136 
observed that the average expression of genes which undergo hypermethylation is 137 
attenuated in naïve compared to primed hESCs, but that hypermethylated genes are 138 
characterised by low average expression in primed hESCs (Figs 2b, 2c). Hypermethylation 139 
may play a functional role in these cells by contributing to downregulation of developmental 140 
pathways, perhaps enhancing pluripotency and blocking differentiation by providing a more 141 
stable gene repression mechanism13. Intriguingly, we observe a subset of genes, notably the 142 
HOX gene family, that become hypermethylated and are upregulated upon hESC resetting 143 
(Fig. 2d), despite no evidence of 5mC oxidation to 5hmC at their promoters (Fig. 2e). 144 
Interestingly, the methylation dynamics of these HOX genes do not differ from genes that 145 
are hypermethylated and downregulated (Fig. 2c, 2d, Supplementary Fig. 4d). This suggests 146 
that there may be population heterogeneity during resetting, whereby a subpopulation of 147 
cells which do not undergo HOX promoter hypermethylation exhibit upregulation of the 148 
genes. 149 
 150 
DNMT3A controls early de novo methylation 151 
 152 
We next sought to identify the epigenetic regulators that are responsible for the deposition 153 
of de novo DNA methylation. Of the de novo DNMT3 family of DNA methyltransferases, 154 
DNMT3B is highly expressed but is transiently downregulated upon resetting. The mRNA 155 
level of DNMT3A is transiently upregulated (Supplementary Fig. 5a), though this is not 156 
reflected in the protein level (Supplementary Fig. 5g). The catalytically inactive DNMT3L is 157 
upregulated (Supplementary Fig. 5a) and considered a marker of naïve pluripotency20. We 158 
generated constitutive knockdown primed hESC cell lines using two short hairpin RNAs 159 
(shRNAs) targeting each of the three genes, as well as one specifically targeting the long 160 
isoform of DNMT3A, known as DNMT3A1 (Supplementary Fig. 5b). We subjected each of 161 
the cell lines to resetting until the early transition, at which stage hypermethylation is 162 
already detectable, and thereafter to the late transition. In the early transition, knockdown 163 
of DNMT3B and DNMT3L had little impact on the level of methylation (Fig. 3a, 164 
Supplementary Fig. 5c). Knockdown of DNMT3A, however, was able to abolish 165 
hypermethylation (Fig. 3a). A recent study demonstrated isoform-specific recruitment of 166 
DNMT3A1 to bivalent CGIs in mouse embryonic stem cells21. However, specific knockdown 167 
of DNMT3A1 had no impact on the level of hypermethylation (Supplementary Fig. 5d), 168 
suggesting that the more dominantly expressed DNMT3A2 carries out de novo methylation 169 
early during resetting, independently of DNMT3L. It is worth noting, however, that during 170 
the late transition of resetting, both DNMT3A and DNMT3B knockdown cells show a partial 171 
reduction in methylation compared to the control cells (Fig. 3b). This indicates that 172 
DNMT3B, which by this stage is transcriptionally expressed at a higher level than during the 173 
early transition (Supplementary Fig. 5a), contributes to hypermethylation along with 174 
DNMT3A. Additionally, when we reset either DNMT3A or DNMT3B knock down cells to the 175 
naïve state, we see a reduction in the pluripotency of the cells as measured by their alkaline 176 
phosphatase activity as well as reduced expression levels of naïve pluripotency genes in 177 
DNMT3A but not DNMT3B knock down cells (Figs 3c, 3d, Supplementary Fig. 5e). As both 178 
DNMT3A and DNMT3B seem to contribute to hypermethylation during the late transition of 179 
resetting, we additionally generated a double knock down cell line of the two genes in 180 
primed hESCs and subjected the cells to resetting to the naïve state (Supplementary Fig 5f). 181 
The DNMT3A/DNMT3B double knock down cells show significantly reduced levels of 182 
hypermethylation during the early transition as well as in naïve hESCs, and they exhibit 183 
reduced pluripotency as measured by their alkaline phosphatase activity and expression 184 
levels of naïve pluripotency genes, though TFCP2L1 and KLF4 do not change significantly 185 
(Figs 3e-g). Collectively, this indicates a putative role of the de novo methyltransferases in 186 
stabilization of the naïve pluripotent state.  187 
 188 
Aside from the de novo methyltransferases, we also hypothesised that loss of ten-eleven 189 
translocation (TET) enzymes may be the cause of bivalent CGI hypermethylation22,23. TET1 is 190 
expressed in primed hESCs and subsequently downregulated at the protein level as hESCs 191 
progress through the early transition of resetting (Supplementary Figs 6a, 6b). We 192 
generated TET1-overexpressing primed hESCs (Supplementary Figs 6c, 6d) and subjected 193 
them to resetting until the early transition. We measured DNA methylation at selected 194 
target loci but observed no change in the levels of DNA methylation, though TET1 is 195 
modestly overexpressed (Supplementary Fig. 6e). These data indicate that 196 
hypermethylation of bivalent loci upon resetting is independent of TET1 loss. 197 
 198 
To determine whether de novo methylation is strictly correlated with the acquisition of 199 
naïve pluripotency during resetting, we used a published cell-surface marker, SUSD2, that 200 
has been shown to separate naïve from primed hESCs during resetting24, and is able to 201 
identify increasing numbers of naïve hESCs during the transition to the naïve state 202 
(Supplementary Fig. 7a). We sorted SUSD2+ and SUSD2- cells during the early and late 203 
transition of resetting and used a targeted approach to measure DNA methylation at 204 
selected resetting -associated hypermethylated loci (Fig. 4a). We observed no significant 205 
difference in the level of hypermethylation in SUSD2+ and SUSD2- fractions, though SUSD2+ 206 
cells displayed higher expression of naïve pluripotency genes (Figs. 4b, 4c, Supplementary 207 
Fig. 7b). In conjunction with the observation that reduced expression of de novo 208 
methyltransferases during resetting impacts naïve pluripotency, this indicates that while de 209 
novo methylation may be important for the stability of the naïve pluripotent state, it is 210 
insufficient for the acquisition of naïve pluripotency. Collectively, this suggests that the 211 
hypermethylation is more a feature of the heterogeneous intermediate population of 212 
partially reset cells. 213 
 214 
Bivalent CGIs that lose H3K4me3 gain DNA methylation 215 
 216 
To investigate the mechanism of bivalent CGI hypermethylation, we first classified bivalent 217 
regions as those possessing H3K4me3 and H3K27me3 peaks in primed hESCs utilising the 218 
ENCODE ChIP-seq data-set. We observed that only 41% of these loci gain DNA methylation 219 
upon resetting (Fig. 5a), indicating that the presence of bivalent chromatin is not sufficient 220 
for acquiring de novo DNA methylation upon resetting. We therefore divided all bivalent 221 
regions in primed hESCs into those that do and do not gain methylation during resetting 222 
(hypermethylated regions defined as >10% increase in naïve vs primed hESC). Taking the 223 
nearest gene to each region (within 1500bp of the TSS), GO analysis of the bivalent 224 
hypermethylated group showed a strong enrichment for developmental pathways, while 225 
the bivalent non-hypermethylated group showed much lower enrichment of other 226 
biological processes (Fig. 5a). This points towards common regulation of the developmental 227 
genes that exhibit hypermethylation during resetting. 228 
  229 
We hypothesized that there are intrinsic differences between bivalent regions that do and 230 
do not gain methylation, which both begin with similar chromatin states. As DNA 231 
methylation and H3K4me3 are known to be mutually exclusive25, we performed ChIP-qPCR 232 
of H3K4me3 at bivalent DNA regions, across the time course of resetting. We observed a 233 
loss of H3K4me3 at bivalent regions that become hypermethylated, whilst bivalent non-234 
hypermethylated regions retain their levels of H3K4me3 (Fig. 5b). In contrast, the levels of 235 
H3K27me3 exhibit little change, despite the presence of DNA methylation (Fig. 5c). While 236 
H3K27me3 and DNA methylation are considered to be mutually exclusive at CpG rich 237 
regions during development26, co-existence of the two modifications has previously been 238 
reported27. It is known that loss of H3K4me3 is permissive to the gain of DNA methylation, 239 
but this on its own cannot explain the specific gain of methylation at these regions, as both 240 
DNMT3A and DNMT3B possess an ADD domain capable of mediating the interaction of the 241 
enzymes with unmethylated H3K425,28-30, and several loci that have been shown to lose 242 
H3K4me3 in naïve hESCs do not undergo hypermethylation14. Additionally, despite 243 
comparable absolute protein levels of DNMT3A and DNMT3B, as measured by mass 244 
spectrometry (Supplementary Fig. 5g), only DNMT3A deposits DNA methylation during the 245 
early transition of hESC resetting. Moreover, the strong bias towards developmental genes 246 
suggests that the gradual hypermethylation is not a stochastic process. 247 
 248 
Transcription factors influence hypermethylation 249 
 250 
Our data led us to hypothesize that an additional player, likely a DNA-binding factor, 251 
facilitates DNMT3A-mediated hypermethylation in the early stages of hESC resetting. To 252 
understand the unique properties of the bivalent hypermethylated group, we performed 253 
differential motif analysis of these regions, with the bivalent non-hypermethylated regions 254 
as a control set. We identified a number of motifs corresponding to DNA-binding 255 
transcription factors enriched at regions that undergo hypermethylation (Fig. 6a). To test 256 
whether these proteins are expressed, we performed total proteomics of primed and early 257 
transition hESCs and identified proteins that were upregulated during the early transition 258 
compared to primed hESCs (Fig. 6b). Through cross-comparison of the two analyses, we 259 
short-listed two candidate transcription factors, SOX15 and NFKB1, which are upregulated 260 
during early resetting and show an enrichment of binding sites at hypermethylated regions 261 
(Figs 6a, 6b). We identified an additional two candidate transcription factors, FOXC1 and 262 
ZFHX3 (Fig. 6a), which were transcriptionally upregulated during the early transition based 263 
on RNA-seq data but not detected in any samples by proteomic analysis, likely due to 264 
technical limitations of the method in detecting nuclear transcription factors31. We 265 
generated constitutive knockdown cell lines using two shRNAs targeting each of the four 266 
candidate genes (Supplementary Fig. 8a) and subjected each of the cell lines to resetting 267 
until the early transition. We measured the expression of naïve pluripotency genes to test 268 
whether the knock down cells undergo resetting similarly to control cells, and found that 269 
their expression is not significantly altered in the knock downs compared to control cells 270 
(Supplementary Fig. 8b). Strikingly, upon resetting, knock down of each of the transcription 271 
factors reduced the level of hypermethylation at target loci analysed, suggesting that the 272 
transcription factor network active during the early transition of resetting is involved in 273 
bivalent promoter CGI hypermethylation (Fig. 6c). The impact of each of the knockdowns on 274 
DNA methylation is higher in regions where at least one of the highly expressed 275 
transcription factors are predicted to bind compared to sites that are not bound by any of 276 
the four transcription factors (Fig. 6c). Interestingly, the reduction in methylation is 277 
observed in each of the transcription factor knock downs at SOX15 and NFKB1 predicted 278 
binding sites, indicating that the impact is not limited to the specific binding sites for each 279 
transcription factor (Fig. 6c). This points to a network synergy in preferentially mediating de 280 
novo methylation at these sites. As the reduction in DNA hypermethylation upon 281 
transcription factor knockdown is only partial, however, this suggests that additional 282 
mechanisms are also at play.   283 
 284 
To test whether signalling changes associated with factors required for induction of the 285 
naïve state induction could explain such a mechanism, we conducted hESC resetting until 286 
the early transition, each time removing one of these factors. Resetting in the absence of 287 
the MEK inhibitor or GSK3β inhibitor or concomitant removal of both inhibitors still resulted 288 
in hypermethylation at target loci analysed (Fig. 6d), suggesting that hypermethylation may 289 
be coordinated by the overexpressed NANOG and KLF2 or the associated pluripotency 290 
network. Collectively, these data indicate that upon reprogramming hESCs to the naïve 291 
state, hypermethylation is driven by the transcription factor network that becomes active 292 
upon resetting, and that this is synchronised by the core pluripotency network.  293 
 294 
Resetting-associated hypermethylation is mirrored in cancer  295 
 296 
De novo DNA methylation of bivalent chromatin in the context of a hypomethylated 297 
genome has also been reported in cancer cell lines and primary tumours32,33. To investigate 298 
the link between the hypermethylation patterns associated with hESC resetting and the re-299 
emergence of such patterns in cancer, we compared hypermethylated CpGs at each stage of 300 
resetting with regions previously identified as hypermethylated in B-cell chronic lymphocytic 301 
leukaemia (B-CLL)34. We observed that the most substantial overlap is found between 302 
hypermethylated CpGs associated with the late transition of resetting and B-CLL 303 
hypermethylation, corresponding to the peak of hypermethylation we observe during 304 
reprogramming (Supplementary Fig. 9a). Interestingly, we also see a more significant 305 
overlap between hypermethylated regions in B-CLL or colon cancer34,35 and resetting -306 
associated hypermethylated CpGs with a low basal methylation level (<5%) in primed hESCs 307 
(Supplementary Figs 9b, 9c). These data demonstrate a substantial overlap between naïve 308 
stem cell and cancer hypermethylation.  309 
We further hypothesised that cancer cells may recapitulate the dichotomy between bivalent 310 
genes that do and do not become hypermethylated. To test this, we compared resetting -311 
associated bivalent hypermethylated and non-hypermethylated CpGs with data from the 312 
cancer genome atlas (TCGA) pan-cancer atlas36,37. We found a significant gain in methylation 313 
between normal and cancer tissue for bivalent CpGs identified as hypermethylated during 314 
the resetting process, compared to unmethylated bivalent CpGs (Fig. 7a, Supplementary Fig. 315 
10a). This was consistent across all cancer types analysed. In addition, when we defined 316 
CpGs that were hypermethylated compared to normal tissues across cancer types, we found 317 
that they were significantly enriched in hESC hypermethylated bivalent CpGs (Fisher’s test p-318 
value < 2x10-16, percentage fold-change 11.13, Fig. 7b). Similar results were also observed 319 
when defining hypermethylated CpGs for each of the 9 individual tumour types (Fig. 7b). 320 
Together these results indicate that resetting -associated hypermethylation parallels pan-321 
cancer hypermethylation, though the individual CpGs methylated in each cancer type vary38. 322 
We see no further enrichment of resetting -associated hypermethylated CpGs with more 323 
advanced stages of cancer (Supplementary Fig. 9d), or with datasets derived from 324 
metastatic tissues (Supplementary Fig. 9e).  325 
To further investigate the parallels between hypermethylation in naïve hESCs and cancer, 326 
we asked whether the regions hypermethylated in naïve hESCs were also marked by 327 
H3K27me3 in normal human tissues that give rise to cancers. By examining H3K27me3 ChIP-328 
seq from 8 normal tissues, we found that the regions surrounding hypermethylated CpGs 329 
had significantly higher levels of H3K27me3 than non-hypermethylated CpGs from naïve 330 
hESCs (Fig. 7c, Supplementary Fig. 10b). This included the HOX loci which we had seen to be 331 
strongly hypermethylated in naïve hESCs as well as loci which are previously reported as 332 
gaining DNA methylation in cancer such as SFRP1 (Fig. 7d)8. 333 
Together, these results demonstrate that resetting of primed hESCs to naïve pluripotency 334 
and cancer follow similar epigenetic trajectories, both involving the acquisition of DNA 335 
methylation at developmental gene promoters marked by H3K27me3. There is growing 336 
evidence in the literature regarding the acquisition of stem-like properties and expression of 337 
pluripotency genes in cancers10,39. This makes it intriguing to speculate that the pluripotency 338 
network plays a key role in establishing cancer hypermethylation. Considering the causal 339 
relationship between hypermethylation and acceleration to one-step transformation9, this 340 
warrants further investigation of means to disrupt de novo accumulation of DNA 341 
methylation at CGI promoters. 342 
 343 
 344 
Discussion 345 
 346 
We propose the concept that reprogramming events during primed to naïve resetting are a 347 
fundamental feature of human cancers and possibly a very early step in cancer evolution. 348 
Although naïve stem cells and cancer cells seem developmentally distant, our data supports 349 
the hypothesis that cancers follow an evolutionary trajectory towards an embryonic stem 350 
cell state, which allows both self-renewal and differentiation10.  351 
 352 
We demonstrate the dynamic acquisition of DNA methylation, primarily at CGI promoters, 353 
upon the transition from primed to naïve pluripotency in hESCs. We observed the highest 354 
levels of hypermethylation in the heterogeneous population of cells present during the late 355 
transition of resetting. It is worth noting that during the late transition of resetting, there is 356 
population heterogeneity as demonstrated by the study of HOX gene promoters, as well as 357 
heterogeneous expression of naïve stem cell markers as exemplified by the SUSD2 358 
expression, but the hypermethylation and expression of naïve stem cell markers do not 359 
strictly co-occur. It seems that hypermethylation is a feature of this heterogeneous 360 
intermediate population of partially reset cells, and it is partially maintained as the cells 361 
stabilise in the naïve state. 362 
 363 
We demonstrate that the hypermethylation that we observed upon the transition from 364 
primed to naïve pluripotency mirrors the frequently observed aberrant hypermethylation in 365 
human cancers. Such parallels have been drawn previously in other mammalian species and 366 
developmental contexts40. However, the data we present here demonstrates 367 
hypermethylation conserved across in vitro and in vivo human pluripotency17, strengthened 368 
by its reproducibility across multiple in vitro resetting methods14,16. Moreover, it is notable 369 
that we do not observe comparable hypermethylation in the mouse ICM or in in vitro mouse 370 
ESCs cultured with 2i inhibitors. This observation has potential implications for making 371 
inferences with regards to epigenetic processes between species, both in development and 372 
in the study of cancer, as has been noted previously41. 373 
 374 
We have observed that bivalent loci are almost exclusively susceptible to DNA 375 
hypermethylation during the transition to naïve pluripotency. However, not all bivalent loci 376 
become hypermethylated, suggesting that the presence of bivalent chromatin is not the 377 
only factor required for acquiring de novo DNA methylation upon resetting. Several studies 378 
have demonstrated that the aberrant gains of DNA methylation observed in cancer also 379 
occur at H3K27me3-marked loci42-44. Loci that gain DNA methylation in cancer are also 380 
enriched in sets of loci that are bivalent in embryonic stem cells33,42,45. The mechanistic basis 381 
of this relationship is unclear. Although DNMTs can interact with EZH2 which is responsible 382 
for deposition of H3K27me346, recruitment of DNMT3A by PRC2 is not sufficient to trigger 383 
de novo DNA methylation47. It is particularly noteworthy that bivalent loci that undergo 384 
hypermethylation both upon resetting and in the context of cancer belong to 385 
developmental pathways33, distinguishing them from other bivalent loci that do not gain 386 
methylation despite having a comparable starting chromatin configuration.  387 
 388 
Our data indicates that DNMT3A is responsible for DNA hypermethylation during the early 389 
transition of primed to naïve resetting, and that both DNMT3A and DNMT3B contribute to 390 
hypermethylation during the late transition of resetting. At this stage, the reduction in 391 
methylation is only partial upon knockdown of either enzyme, therefore alternative factors 392 
such as the putative de novo activity of DNMT1 cannot be excluded48. A knockdown of 393 
either DNMT3A or DNMT3B impacted the stability of the naïve state as measured by 394 
alkaline phosphatase activity, with a knockdown of DNMT3A additionally disrupting the 395 
naïve transcriptional network. Interestingly, a double knockdown of DNMT3A and DNMT3B 396 
had an even greater impact on the naïve state as measured by alkaline phosphatase activity, 397 
suggesting a synergy between the two de novo methyltransferases in influencing either the 398 
transition to the naïve state or naïve cell stability. It remains to be deduced whether 399 
DNMT3A/DNMT3B impact the naïve state through the hypermethylation they contribute to 400 
or through a non-catalytic role. Additionally, in order to better understand the functional 401 
impact of resetting -associated hypermethylation, its potential impact on the differentiation 402 
potential of the naïve cells remains to be investigated independently of the known roles of 403 
de novo methyltransferases in stem cell differentiation. 404 
 405 
Our data points towards the transcription factor network established upon resetting playing 406 
a role in the targeting or recruitment of DNMT3A to loci that gain methylation. Whilst we 407 
cannot currently differentiate between a direct interaction of DNMT3A with transcription 408 
factors or an indirect network-driven effect on targeting of the enzyme, loci-specific 409 
recruitment of DNMT3A via transcription factors has been previously demonstrated49 and in 410 
vitro data supports the ability of DNMT3A to interact directly with numerous transcription 411 
factors50. Our data are also indicative of the overexpressed NANOG and KLF2 coordinating 412 
de novo methylation, however studies have shown that KLF2 is not expressed in vivo in the 413 
human inner cell mass51,52, where we also observe hypermethylation. Additionally, we 414 
observe comparable hypermethylation in naïve hESCs generated using two transgene-415 
independent methods of resetting. This collectively suggests that the core pluripotency 416 
network, to which NANOG belongs, is likely responsible for coordinating the transcriptional 417 
changes that drive DNA hypermethylation. There is growing evidence in the literature 418 
regarding the acquisition of stem-like properties and expression of pluripotency genes in 419 
cancers10,39. This makes it intriguing to speculate that a transcriptional programme 420 
associated with the naïve pluripotency network could drive a shared mechanism of 421 
hypermethylation during resetting of primed hESCs to naïve pluripotency and in cancer 422 
development, either preceding or in conjunction with genetic mutations.  423 
 424 
Hypermethylation during primed to naïve resetting affects developmental genes whose 425 
expression is generally low and is further attenuated upon hypermethylation, as is often 426 
observed in cancer33,38. The function of hypermethylation in cancer remains a topic of 427 
debate. While several studies have shown clear repressive roles of hypermethylation for 428 
individual tumour suppressor genes7,53, it remains less well understood what the purpose of 429 
hypermethylation of a large number of loci might be. It has been proposed that aberrant 430 
hypermethylation in cancer may act to block cellular differentiation, thus enabling cancer 431 
cells to continue to propagate in their more primitive states33,44,54, and this has been 432 
experimentally demonstrated in a recent study9. During reprogramming of somatic cells to 433 
induced pluripotent stem cells (iPS), global DNA demethylation occurs late55 and is a 434 
bottleneck for efficient reprogramming56. Our data indicates that in addition to global DNA 435 
demethylation which is efficiently erased in further naïve resetting, gain of DNA methylation 436 
in bivalent developmental gene promoters will lock cells in a primitive state. The 437 
commonality in methylation patterns across cancer types, each harbouring different driver 438 
mutations, suggests that these methylation changes may by regulated by a common 439 
overarching mechanism and occur early in tumourigenesis, as has been demonstrated 440 
previously in one of the few models of early cancer development57. In line with this, the 441 
notion that cancer cells follow an evolutionary trajectory towards a stem cell state10,39 442 
makes the transition from primed to naïve pluripotency an interesting model to study 443 
biological processes such as DNA methylation that likely occur early during cancer initiation, 444 
and may be analogous to dedifferentiation. Additional molecular features of the primed to 445 
naïve state transition appear analogous to cancer hallmarks58, such as altered metabolism12, 446 
loss of imprints15, loss of DNA hydroxymethylation59 and genomic instability11,15,60. Whether 447 
they are related to the changing epigenetic landscape remains unexplored, but further use 448 
of this model system may shed light on the emergence of these characteristics during 449 
cellular transformation. We propose that naïve resetting may provide a good model system 450 
to understand whether other molecular processes associated with cellular reprogramming 451 
play a role in tumourigenesis. 452 
 453 
Methods 454 
 455 
Cell lines  456 
WA09/H9 NK2 primed hESCs were kindly provided by Austin Smith12 with permission from 457 
WiCell. All hESCs were cultured on irradiated mouse embryonic fibroblasts (iMEF). iMEFs 458 
were seeded at a density of 1x106 cells per 6-well plate, in 5% O2, 7% CO2 at 37°C in a 459 
humidified incubator. 460 
 461 
Cell culture  462 
Primed H9-NK2 cells containing doxycycline-inducible KLF2 and NANOG transgenes coupled 463 
to Venus were maintained in conventional medium (KSR/FGF) comprised of DMEM/F-12 464 
(Sigma Aldrich) with 20% KSR (ThermoFisher Scientific) and 10ng per ml basic fibroblast 465 
growth factor (bFGF; Peprotech), supplemented with 2mM L-glutamine (ThermoFisher 466 
Scientific), 100uM 2-mercaptoethanol (2ME) (ThermoFisher Scientific), 1% MEM non-467 
essential amino acids (ThermoFisher Scientific), and 50mg per ml Penicillin-Streptomycin. 468 
Cultures were passaged every 5-6 days as small clumps by dissociation with a buffer 469 
containing 1mg per ml Collagenase IV (ThermoFisher Scientific), 0.025% Trypsin 470 
(ThermoFisher Scientific), 1mM CaCl2 and KSR at a final concentration of 20% in PBS. 471 
Medium was changed daily.  472 
Resetting to the naïve state was carried out as previously described12. Conventional human 473 
embryonic stem cells (hESCs) were dissociated to single cells with trypsin and re-plated in 474 
the presence of 10µM Rho-associated kinase inhibitor (ROCKi [Y-27632]; Sigma Aldrich). 475 
After 24 hours, media was changed to primed media with 1µM doxycycline (Sigma Alrich). 476 
The following day, media was changed to 2iL+dox media composed of 50% DMEM/F12 and 477 
50% Neurobasal (ThermoFisher Scientific) supplemented with 2mM L-glutamine, 100µM 478 
2ME, N2 (ThermoFisher Scientific), B27 (ThermoFisher Scientific), 1µM PD0325901 479 
(StemCell Technologies), 1µM CHIR99021 (StemCell Technologies), human recombinant LIF 480 
(Peprotech), 1x Penicillin-Streptomycin and 1µM doxycycline. Media was changed daily. 481 
Cells were split every 4-5 days after dissociation to single cells using Accutase (Sigma 482 
Aldrich). After 2 weeks, doxycycline was withdrawn and PKC inhibitor Gö6983 (Sigma 483 
Aldrich) was added at a concentration of 5µM. Cells in 2iL+Gö were split every 4-5 days after 484 
dissociation to single cells using Accutase.  485 
 486 
Stable knock down or overexpression cell line generation 487 
Short hairpin RNA (shRNA) constructs were obtained from Dharmacon in the TRC pLKO.1 488 
lentiviral vector. Sequences are listed in Supplementary Table 1. Knock down of DNMT3A2 489 
was not carried out due to an inability to design an effective shRNA against its single unique 490 
exon. Entry clone for overexpression of TET1 was obtained from Harvard PlasmID 491 
Repository (TET1 in pENTR223; HsCD00399189) and a recombination reaction was 492 
performed with the pLenti CMV puro DEST (w118-1) destination vector with Gateway LR 493 
clonase II (ThermoFisher Scientific) to generate expression vectors. To generate lentiviral 494 
particles, HEK293T cells were transfected with the shRNA plasmid or expression vector for a 495 
target gene, the packaging construct pCMV Δ8.91, and a vesicular stomatitis virus 496 
glycoprotein (VSV-G) containing envelope expressing plasmid pMD2.G, using jetPrime 497 
(Polyplus) at a ratio of 1:2. Primed hESCs were treated with 6µg per ml polybrene (Sigma 498 
Aldrich), transduced with filtered lentiviral particles, and stable hESC knock down or 499 
overexpression cell lines were generated by puromycin selection (1µg per ml) of 500 
successful integrants.   501 
 502 
Western Blotting 503 
Whole cell lysates were extracted in RIPA buffer (Sigma Aldrich), with protease inhibitor 504 
cocktail (Sigma Aldrich). Proteins (concentration determined by BCA assay) were separated 505 
by electrophoresis on a 4-12% Bis-Tris gel in MOPS running buffer (ThermoFisher Scientific) 506 
and then transferred to polyvinylidene difluoride (PVDF) membranes (Merck Millipore). 507 
Membranes were blocked with 5% skimmed milk for 45 min at room temperature and 508 
incubated overnight at 4ᵒC with primary antibody (TET1: Source Bioscience; GTX124207 at 509 
1:1000 and GAPDH: Cell Signalling Technologies; 2118S at 1:2500) in blocking buffer. 510 
Membranes were incubated for 1 hour at room temperature with horseradish peroxidase-511 
conjugated secondary antibodies sheep-anti-mouse IgG or sheep-anti-rabbit IgG (1:5,000; 512 
GE Healthcare; NA931, NA934). Membranes were washed in 0.1% Tween-20 in PBS (PBST), 513 
and detection was performed with enhanced chemiluminescence (ThermoFisher Scientific), 514 
with visualisation on the Amersham Imager 600 (GE Healthcare). Uncropped blots are 515 
provided in Supplementary Fig. 11.  516 
 517 
qPCR 518 
Cells were dissociated to single cells using Accutase and serially plated for 2 hours to 519 
eliminate excess iMEFs. Total RNA was isolated from pelleted hESCs using the Direct-zol RNA 520 
mini-prep kit (Zymo) and treated with the DNA-free™ DNA removal kit (ThermoFisher 521 
Scientific). Complementary DNA (cDNA) was made using a high-capacity RNA to cDNA kit 522 
(ThermoFisher Scientific). Real-time PCR was carried out using one-step Sybr green reaction 523 
mix (Bio-Rad) on the CFX384 Touch™ Real Time PCR detection system (Bio-Rad). An 524 
endogenous control (GAPDH) was used to normalise expression. Primer sequences are listed 525 
in Supplementary Table 2. 526 
 527 
Chromatin Immunoprecipitation 528 
Cells were cross-linked with 1% formaldehyde for 10 minutes at room temperature with 529 
gentle rocking, after which the formaldehyde was quenched with 1.25M glycine. Chromatin 530 
was then extracted from the cross-linked cells using the chromatin extraction kit (Abcam), 531 
as per the manufacturer’s instructions. The extracted chromatin was then fractionated by 532 
sonication at 4° (12 cycles of 15s on, 60s off; Diagenode Bioruptor® Plus). The size of the 533 
sonicated chromatin was then checked by agarose gel electrophoresis. Chromatin 534 
immunoprecipitation was carried out using the ChIP – One Step kit (Abcam) with a starting 535 
total of 5µg of chromatin. Immunoprecipitation was carried out as per the manufacturer’s 536 
instructions and the following quantites of antibody were used for immunoprecipitation; 537 
H3K4me3 0.5µg (Abcam; ab8580), H3K27me3 2µg (Abcam; ab195477). As a loading control 538 
for assessing immunoprecipitation we isolated input DNA for each sample, which represent 539 
the starting quantity of chromatin prior to immunoprecipitation. Input and 540 
immunoprecipitated DNA were quantified by real-time PCR, and data is shown as the % 541 
enrichment relative to the input for each sample. Primer sequences are listed in Table 3. 542 
 543 
Bisulfite Sequencing Analysis 544 
Bismark coverage files downloaded from GEO were uploaded into SeqMonk (v1.41.0), 545 
where the genomes were binned into 300bp probe windows. Methylation quantitation 546 
was carried out using the ‘Bisulphite methylation over features’ pipeline in SeqMonk 547 
(v1.41.0), with a 300bp probe carried forward if it contained at least 5 CpGs each with at 548 
least 3 counts. Motif enrichment analysis was performed using the analysis of motif 549 
enrichment (AME) tool on the MEME suite (v5.0.4)61, searching against the human 550 
HOCOMOCO (v11 FULL) database. Sequences were scored using the average odds score 551 
and motif enrichment calculated using Fisher’s exact test. 552 
Overlap analysis 553 
Overlap analysis was performed in R using the package regioneR (Version 3.8: 554 
https://bioconductor.org/packages/release/bioc/html/regioneR.html). Overlap was 555 
performed using the ‘overlapPermTest’ function with 1000 permutations. Random 556 
regions were generated for the hg19 genome using the ‘circularRandomizeRegions’ 557 
function. Random loci generation was restricted to loci present in the Illumina EPIC array 558 
(for overlaps performed with Illumina EPIC array probes) or to regions with a (G+C) 559 
fraction >0.55 and a CpG observed-to-expected ratio >0.6 (for overlaps performed with 560 
bisulfite sequencing data). ENCODE and ChromHMM data for the H1 hESC cell line were 561 
downloaded from the UCSC genome browser. For ENCODE data, StdPk files were 562 
downloaded for each histone modification and genomic coordinates extracted (as BED 563 
files) for use in the overlap analysis. 564 
Mass Spectrometry of Nucleosides  565 
Genomic DNA was digested using DNA Degradase Plus (Zymo Research) according to the 566 
manufacturer’s instructions and nucleosides were analysed by LC-MS/MS on a Q-Exactive 567 
mass spectrometer (Thermo Scientific) fitted with a nanoelectrospray ion-source (Proxeon). 568 
All samples and standards had a heavy isotope-labelled nucleoside mix added prior to mass 569 
spectral analysis (2'-deoxycytidine-13C1, 15N2 (Santa Cruz), 5-(methyl-2H3)-2'-deoxycytidine 570 
(Santa Cruz), 5-(hydroxymethyl)-2'-deoxycytidine-2H3 (Toronto Research Chemicals). MS2 571 
data for 5hmC, 5mC and C were acquired with both the endogenous and corresponding 572 
heavy-labelled nucleoside parent ions simultaneously selected for fragmentation using a 5 573 
Th isolation window with a 1.5 Th offset. Parent ions were fragmented by Higher-energy 574 
Collisional Dissociation (HCD) with a relative collision energy of 10%, and a resolution setting 575 
of 70,000 for MS2 spectra. Peak areas from extracted ion chromatograms of the relevant 576 
fragment ions, relative to their corresponding heavy isotope labelled internal standards, 577 
were quantified against a six-point serial 2-fold dilution calibration curve, with triplicate 578 
runs for all samples and standards. 579 
 580 
Targeted bisulfite sequencing 581 
Bisulfite PCR primers were designed against an in silico bisulfite converted reference 582 
sequence using the Bisulfite Primer Seeker software (Zymo) or Methprimer (Urogene), and 583 
universal Illumina adapter sequences were added to the 5’ end of each primer. Cells were 584 
dissociated to single cells using Accutase and serially plated for 2 hours to eliminate excess 585 
iMEFs. DNA was isolated from pelleted cells using the PureLink Genomic DNA mini kit 586 
(ThermoFisher Scientific). Bisulfite conversion of DNA was carried out using the Imprint® 587 
DNA Modification kit (Sigma Aldrich), following the manufacturer’s instructions. The 588 
modified DNA was amplified using the loci specific bisulfite PCR primers (listed in 589 
Supplementary Table 4) and HotStar Taq DNA Polymerase (Qiagen). The PCR conditions 590 
were as follows: 95 °C for 15 min; 94 °C for 30 seconds; 56 °C for 30 seconds; 72 °C for 1 591 
min; Repeat steps 2-4 29X; 72 °C for 10 min; Hold 12°C. PCR products were purified using 592 
SPRI beads (Agencourt AMPure XP, Beckman Coulter). Amplicons were PCR amplified 593 
with 8 cycles using a universal Illumina forward primer and an indexed reverse primer 594 
and quantified with the Kapa Library quantification kit for Illumina (Roche). For larger 595 
experiments, multiplex targeted bisulfite sequencing was performed using the 48x48 596 
layout on the Fluidigm C1 system (Fluidigm), coupled with Illumina MiSeq sequencing. 597 
Fluidigm primers are listed in Supplementary Table 5. Amplicons from a single sample 598 
were pooled and sequencing was performed on an Illumina MiSeq with 150bp paired-end 599 
reads, using v3 chemistry, at Barts and the London Genome Centre (London, UK). Reads 600 
were quality trimmed and mapped to a personalised human genome composed of 601 
amplicon sequences, using Bismark (v.0.19.0), followed by extraction of methylation calls.  602 
 603 
Infinium MethylationEPIC BeadChip assay 604 
Genomic DNA was extracted using the PureLink Genomic DNA mini kit (ThermoFisher 605 
Scientific). Bisulfite conversion of DNA was carried out using the Imprint® DNA Modification 606 
kit (Sigma Aldrich), following the manufacturer’s instructions. Infinium MethylationEPIC 607 
BeadChip assay (Illumina) was performed according to manufacturer instructions by Barts 608 
and the London Genome Centre (London, UK). The Bioconductor package ChAMP (version 609 
2.11.3: https://bioconductor.org/packages/release/bioc/html/ChAMP.html) was used to 610 
process raw Infinium idat files using the GRCh37 human genome manifest file. 611 
TCGA Analysis 612 
Illumina 450K DNA Methylation data spanning 396965 CpGs and 9664 samples was 613 
downloaded from the Pan Cancer Atlas (https://gdc.cancer.gov/about-614 
data/publications/pancanatlas). All samples from individuals without both a tumour and 615 
normal tissue sample were removed. Samples from tumour types with less than 30 616 
individuals were removed. In order to assess only CpGs deemed “bivalent”, CpGs outside of 617 
regions that showed a peak of H3K27me3 and H3K4me3 in ENCODE H1 hESCs were 618 
removed. For this analysis, raw infinium IDAT files from the hESC resetting experiment were 619 
processed using minfi and normalised via the singlesample Noob method62. CpGs used for 620 
analysis were filtered for those that are unmethylated in primed hESCs (mean beta < 0.3). 621 
Unmethylated probes were restricted to those CpGs with mean Beta < 0.3 during the 622 
primed to naïve transition. Hypermethylated hESC probes were defined using ChAMP and 623 
restricted to those CpGs with ΔBeta > 0.1 in either the early transition, late transition or 624 
naïve state. Probes hypermethylated in cancer were also defined using ChAMP, and similarly 625 
restricted to those CpGs with ΔBeta > 0.1 between normal tissue and tumour samples. The 626 
overlap enrichment of cancer hypermethylated and hESC hypermethylated regions was 627 
determined via Fisher’s exact test. For the creation of heatmaps, data was first ordered by 628 
sample based on mean methylation of all CpGs, and then by CpG based on mean 629 
methylation across all samples of every cancer type. Statistical significance was calculated 630 
using a paired Wilcoxon test.  631 
 632 
Human Tissue H3K27me3 Analysis 633 
H3K27me3 and control read alignments were downloaded as BAM files for each normal 634 
human tissue examined from ENCODE (https://www.encodeproject.org/)63,64 that 635 
corresponded to the cancers profiled by TCGA, except HSNC for which no obvious 636 
corresponding normal sample was available. Bigwig files for genome browser visualisation 637 
and peaks of H3K27me3 for comparison were obtained in the same way. ENCODE IDs for 638 
each experiment and data file can be found in Supplementary Data 1. To examine 639 
H3K27me3 levels around naïve hypermethylated CpGs, windows of 500bp was defined 640 
centred around each CpG. ChIP-seq read counts/window were calculated using BEDtools’ 641 
coverage function. Read counts were scaled to counts per 10 million based on total number 642 
of mapped reads/sample and divided by the input read count to provide a normalised read 643 
count. To prevent windows with zero reads in the input sample generating a normalised 644 
count of infinity, an offset of 0.5 was added to all windows prior to scaling and input 645 
normalisation. Regions where coverage was 0 in all samples were removed from the 646 
analysis. A similar procedure was used to generate heatmaps of H3K27me3 levels, using 647 
multiple 250bp windows to span 5kb on either side of each CpG. Colour scales for ChIP-seq 648 
heatmaps range from the minimum to the 90% quantile of the normalised read count. 649 
 650 
Analysis of 5hmC by glucMS-qPCR 651 
Genomic DNA was treated with T4 Phage β-glucosyltransferase (T4-BGT; NEB) according to 652 
the manufacturer’s instructions. Glucosylated genomic DNA was digested with 10 U of 653 
either HpaII, MspI or no enzyme (mock digestion) at 37 °C overnight, followed by 654 
inactivation for 20 min at 80 °C. The HpaII- and MspI-resistant fraction was quantified by 655 
qPCR using primers designed around at least one HpaII/MspI site, and normalizing to the 656 
mock digestion control. Resistance to MspI directly translates into percentage of 5hmC, 657 
whereas 5mC levels were obtained by subtracting the 5hmC contribution from the total 658 
HpaII resistance. Primers used are listed in Supplementary Table 6.  659 
 660 
Mass Spectrometry-based proteomics 661 
Cells from 3 independent biological replicates per condition were washed twice with ice 662 
cold PBS supplemented with 1 mM Na3VO4 and 1 mM NaF, lysed in urea buffer (8M urea in 663 
20 mM in HEPES pH 8.0, 1 mM Na3VO4, 1 mM NaF, 1mM Na4P2O7 and 1 mM sodium β-664 
glycerophosphate) for 30 min and homogenized by sonication (15 cycles of 30s on 30s off; 665 
Diagenode Bioruptor® Plus). Insoluble material was removed by centrifugation at 20,000 xg 666 
and protein levels in the cell extracts were quantified by bicinchoninic acid (BCA) analysis. 667 
For trypsin digestion, 100 µg of protein was reduced and alkylated by sequential incubation 668 
with 10 mM DTT and 16.6 mM iodoacetamyde for 1h and 30min, respectively. Urea 669 
concentration was diluted to 2 M with 20 mM HEPES (pH 8.0), 80 µL of preconditioned 670 
trypsin beads [(50% slurry of TLCK-trypsin (Thermo-Fisher Scientific; Cat. #20230)] were 671 
added and samples were incubated for 16h at 37C with agitation. Peptide solutions were 672 
desalted using 10 mg OASIS-HLB cartridges (Waters, Manchester, UK). Briefly, OASIS 673 
cartridges were accommodated in a vacuum manifold (-5 mmHg), activated with 1 mL ACN 674 
and equilibrated with 1.5 mL washing solution (1% ACN, 0.1% TFA). Peptides were loaded 675 
into the cartridges, washed with 1 mL of washing solution, eluted with 500 µL of ACN 676 
solution (30% ACN, 0.1% TFA), dried in a speed vac (RVC 2-25, Martin Christ 677 
Gefriertrocknungsanlagen) and stored at -80C. Dried peptides were dissolved in 0.1% TFA 678 
and analysed by nanoflow ultimate 3,000 RSL nano instrument coupled to a Q Exactive plus 679 
mass spectrometer (Thermo Fisher Scientific). Gradient elution was from 3% to 35% solvent 680 
B in 120 min at a flow rate 300 nL/min with solvent A being used to balance the mobile 681 
phase (buffer A was 0.1% formic acid in water and B was 0.1% formic acid in acetonitrile) . 682 
The spray voltage was 1.95 kV and the capillary temperature was set to 255C. The Q-683 
Exactive plus was operated in data dependent mode with one survey MS scan followed by 684 
15 MS/MS scans. The full scans were acquired in the mass analyser at 375-1500 m/z with 685 
the resolution of 70,000 and the MS/MS scans were obtained with a resolution of 17,500. 686 
Overall duty cycle generated chromatographic peaks of approximately 30s at the base, 687 
which allowed the construction of extracted ion chromatograms (XICs) with at least 10 data 688 
points. Mascot Daemon 2.5.0 was used to automate peptide identification from MS data. 689 
Peak list files (MGFs) from RAW data were generated with Mascot Distiller v2.5.1 and 690 
loaded into the Mascot search engine (v2.5) in order to match MS/MS data to peptides. 691 
Searches were performed against the SwissProt Database (release December 2015) with a 692 
FDR of ~1% and restricted to the human entries. Mass tolerance of ±10 ppm for the MS 693 
scans and ±25 mmu for the MS/MS scans, 2 trypsin missed cleavages, carbamidomethyl Cys 694 
as a fixed modification and PyroGlu on N-terminal Gln and oxidation of Met as variable 695 
modifications were allowed. The in-house developed Pescal software was used for label-696 
free peptide quantification as described before65, XICs for all the peptides identified across 697 
all samples were constructed with ±2 min and ±7 ppm retention time and mass windows, 698 
respectively. Peak areas from all XICs were calculated. The maximum intensity value for the 699 
2 technical replicates was selected and used for further analysis. Intensity values for each 700 
peptide were normalized to total sample intensity. Statistical significance was calculated 701 
using two tail unpaired Student’s t-test. Multiplicity correction was performed by applying 702 
the Benjamini-Hochberg method on the p-values, to control the false discovery rate (FDR). 703 
Differences were considered significant when FDR < 0.05. Proteins with a Mascot score > 40 704 
were used for analysis. Data are available in Supplementary Data 2. 705 
RNA-sequencing 706 
Total RNA was extracted using Direct-zol RNA mini kit (Zymo) and DNase treated 707 
(ThermoFisher Scientific), before mRNA was isolated from 500ng of total RNA using 708 
Dynabeads mRNA DIRECT purification kit (ThermoFisher Scientific) and fragmented with 709 
RNA fragmentation reagent (ThermoFisher Scientific). First strand cDNA synthesis was 710 
performed with SuperScript III First-Strand Synthesis System and 3 μg μl−1 random 711 
hexamers (ThermoFisher Scientific) followed by second strand synthesis with DNA 712 
polymerase I and RNase H. After purification using SPRI beads, the double stranded cDNA 713 
was ligated to in house designed adapters (based on TruSeq Indexed adapters (Illumina)) 714 
using NEBNext Ultra II (NEB) followed by 15 cycles of amplification and library 715 
purification. Library size distribution and molarity was assessed by the DNA 1000 assay on 716 
the 2100 Bioanalyzer (Agilent), and libraries were quantified with the Kapa Library 717 
quantification kit for Illumina (Roche). Sequencing was performed on an Illumina NextSeq 718 
with 75bp paired-end sequencing at Barts and the London Genome Centre (London, UK). 719 
Read quality was determined using FASTQC. Genomic mapping of short reads was 720 
performed using hisat2 (v. 2.1.0) to the human genome (GRCh38). Reads were counted 721 
for each sample using FeatureCounts (Subread, v. 1.6.3)66. RNA-sequencing analysis was 722 
performed using the R package EdgeR (v3.18.1)67. Upregulated and downregulated genes 723 
were called as those with Benjamini-Hochberg corrected FDR < 0.05 and a log2 fold 724 
change > 1. Pathway enrichment analysis was performed using DAVID Bioinformatics 725 
Resources68,69. 726 
 727 
Alkaline Phosphatase Assay 728 
Cells were seeded a 96-well plate. After 24 hours, the Amplite™ Colorimetric Alkaline 729 
Phosphatase Assay kit (Stratech) was used to measure alkaline phosphatase activity 730 
according to manufacturer’s instructions. 731 
 732 
Flow cytometry, fluorescence-activated cell sorting (FACS) 733 
Cells were dissociated to single cells with Accutase and washed with 3%FCS/PBS, before 734 
being blocked in 10% FCS/PBS. Cells were resuspended in 2.5ul SUSD2-PE antibody 735 
(Biolegend; 327406) and 5ul anti-feeder-APC antibody (Miltenyi Biotec; 130-120-802) for 15 736 
minutes at 4°C in the dark. Alternatively, following 1 hour pulse labelling with 10um BrdU, 737 
cells were fixed, permeabilised, blocked and stained using the APC BrdU Flow Kit (BD 738 
Pharminogen) following manufacturer’s instructions, with the addition of 5ul of anti-feeder-739 
PE antibody (Miltenyi Biotec; 130-120-166). Cells were wash twice in 3% FCS/PBS and then 740 
stained with DAPI for 15 minutes at 4°C in the dark. Samples were either analysed on an LSR 741 
Fortessa cell analyser (BD Biosciences) or FACS sorted on the BD FACS Aria Fusion cell sorter. 742 
Flow cytometry data analysis was carried out using FlowJo Version 10 software. 743 
 744 
Statistical Analysis 745 
Significance testing was performed using Prism (v.7.04, v.8.4.2) and Student’s T-test, one-746 
way ANOVA or two-way ANOVA with Bonferroni post-hoc tests as specified in the Figure 747 
legends. Where applicable, data are plotted as mean ± SEM. Representative data are 748 
shown where experiments were repeated at least twice with similar results.  749 
Data availability 750 
All datasets have been deposited in the Gene Expression Omnibus and are accessible 751 
under [https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE128130] GSE128130. 752 
Additional data used include ENCODE, ChromHMM and TCGA pan-cancer data, 753 
HOCOMOCO (v11 FULL), SwissProt (Dec 2015 release). Data for human naive resetting 754 
methods was downloaded from GSE60945, GSE76970, GSE90168, data for mouse 2i and 755 
serum ESCs from GSE42923, and data for human and mouse in vivo development from 756 
GSE34864 and GSE49828. The source data for Figs. 2e, 3c-g, 4b-c, 5b-c, 6c-d, and 757 
Supplementary Figs 1a, 1h, 5a-b, 5d-g, 6a-e, 7b, 8a-b are provided as a source data file. 758 
 759 
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Figure Legends 969 
 970 
Figure 1. Primed to naïve resetting induces bivalent CGI promoter hypermethylation. a) 971 
Schematic detailing the model system and time points used in the study. 2iL+dox: 2 small 972 
molecule inhibitors of MEK1/2 and GSK3β (2i), human recombinant leukaemia inhibitory 973 
factor (hLIF; collectively 2iL) and doxycycline. 2iL+Gö: 2iL and a pan-protein kinase C 974 
inhibitor (PKCi), Gö. hESCs, human embryonic stem cells; b) Heatmap showing methylation 975 
levels of the top 10,000 CpG probes that are differentially methylated (Δβ > 0.1, adjPval < 976 
0.05) in the early transition, late transition and naïve hESCs compared to primed hESCs. 977 
Methylation β-value is indicated by the colour key. adjPval based on Benjamini-Hochberg 978 
adjustment. c) Genome browser tracks for Infinium MethylationEPIC data capturing a 979 
representative hypermethylated locus. The heatmap shows the raw methylation β-values 980 
per CpG for each sample, while the subsequent rows show the per-probe difference in 981 
methylation for each time point of resetting compared to primed hESCs. CGIs are 982 
highlighted in green. d) Overlap of hypermethylated probes (n = 91119) with regions of 983 
histone modification enrichment (obtained from the ENCODE ChIP-seq data for hESC cell 984 
line H1: H3K4me1 n = 139971; H3K4me2 n = 73086; H3K4me3 n = 33270; H3K9me3 n = 985 
86122; H3K27me3 n = 25909; H3K36me3 n = 35877; H3K79me2 n = 33205). e) The 986 
proportion of hypermethylated probes (n = 46844 early transition, n = 91119 late transition, 987 
n = 20297 naive) that are marked by H3K4me1/2/3, H3K4me1/2/3 alone, or bivalency 988 
(H3K4me3 and H3K27me3). f) Overlap of late transition hypermethylated probes (n = 91119) 989 
and hypomethylated probes (n = 392,875) with CpG islands (n = 30344). g) Overlap of 990 
hypermethylated and hypomethylated probes (as in 1f) with ENCODE regulatory regions 991 
(promoters or enhancers). h) Proportion of late transition hypermethylated probes (n = 992 
91119) that overlap with ENCODE predicted promoters and enhancers (as defined by 993 
ChromHMM in the hESC cell line H1).  994 
DMP, differentially methylated probes. For overlap analysis, data is presented as the log2 995 
corrected fold increase in the observed overlap compared to the mean overlap of 1000 996 
randomly generated loci. ***P< 0.001. 997 
 998 
Figure 2. Resetting results in hypermethylation and repression of developmental genes. a) 999 
GO term analysis of hypermethylated and hypomethylated genes at the late transition of 1000 
resetting compared to primed hESCs. A gene was classified as hypermethylated if a 1001 
hypermethylated probe was present within 1500bp upstream of the TSS. b) Average gene 1002 
expression for genes that are hypermethylated (average promoter methylation Δβ > 0.1) or 1003 
hypomethylated (average promoter methylation Δβ < 0.1) in naïve compared to primed 1004 
hESCs. Boxes represent the median and interquartile range and error bars represent the 1005 
maximum and minimum values. Statistical significance determined via two-tailed paired 1006 
Wilcoxon test. ***P<0.001, ****P<0.0001. CPM, Counts per Million.  c) Scatter plot of genes 1007 
that are hypermethylated and downregulated showing the average promoter methylation 1008 
(average β-value of CpG probes within 1500bp of TSS) versus the log2 CPM (counts per 1009 
million) for each gene from RNA-seq data. Data for each individual time point is indicated by 1010 
the colour key. d) Scatter plot showing the average promoter methylation of 21 HOX genes 1011 
(average β-value of CpG probes within 1500bp of TSS) versus the log2 CPM for each gene 1012 
from RNA-seq data. Data for each individual time point is indicated by the colour key. e) 1013 
GlucMS-qPCR in primed and late transition hESCs showing the percentage of 5mC (blue) and 1014 
5hmC (orange) per CpG. Bars represent the mean of three biological replicates and error 1015 
bars represent the SEM. Source data are provided as a Source Data file. 1016 
 1017 
Figure 3. Early de novo methylation is dependent on DNMT3A. a&b) Heatmaps showing 1018 
methylation levels in control and DNMT3A/B knock down samples during resetting. 1019 
Heatmap shows the top 17,000 CpG differentially methylated probes (DMP; Δβ > 0.1, p < 1020 
0.05) in the early transition (Fig 3a) and late transition (Fig 3b) compared to primed hESCs 1021 
(in wild type early transition (Fig 3a) or late transition (Fig 3b) compared to primed hESCs 1022 
identified in analysis shown in Fig 1b). Methylation β-value is indicated by the colour key. c) 1023 
qRT-PCR for naïve pluripotency genes in control and knock-down cells, in naïve hESCs. Bars 1024 
represent mean of three biological replicates and error bars represent the SEM. Statistical 1025 
difference between samples was calculated by a one-way ANOVA with a Bonferroni post-1026 
hoc test compared to the control. Human GAPDH was used to normalise expression. d) 1027 
Alkaline phosphatase activity in knock down and control naïve hESCs. Data shown are the 1028 
mean of 2 biological replicates (independent shRNA KD), each with 5 technical replicates. 1029 
Error bars represent SEM. Statistical difference between samples was analysed by a one-1030 
way ANOVA with a Bonferroni post-hoc test compared to the control. e) Alkaline 1031 
phosphatase activity in DNMT3A/DNMT3B double knock down and control naïve hESCs. 1032 
Data shown are the mean of 5 replicates. Error bars represent SEM. Statistical difference 1033 
between samples was analysed by a two-tailed Student’s unpaired t-test. f) qRT-PCR for 1034 
naïve pluripotency genes in control and DNMT3A/DNMT3B double knock-down naïve hESCs. 1035 
Bars represent the mean of three biological replicates and error bars represent the SEM. 1036 
Statistical difference between samples was calculated by a two-tailed Student’s t-test. 1037 
Human GAPDH was used to normalise expression. g) Plot showing % methylation in 1038 
DNMT3A/DNMT3B double knock down and control cells during resetting. Each dot 1039 
represents % methylation of single CpGs (n = 57) from 4 genomic regions analysed by 1040 
targeted bisulfite sequencing. Red bars represent mean methylation for each sample. 1041 
Statistical difference between samples was analysed by a Kruskal-Wallis test, with Dunn’s 1042 
multiple comparisons post-hoc test.  1043 
For all panels, *P<0.05, **P<0.01, ***P<0.001, ***(P<0.0001), N.S. denotes not significant 1044 
(p>0.05). Source data are provided as a Source Data file. 1045 
 1046 
Figure 4. Hypermethylation is a feature of resetting and is not restricted to emerging naïve 1047 
cells. a) Flow cytometry dot plots showing SUSD2-PE staining on the x-axis against anti-1048 
feeder-APC staining on the y-axis for hESCs during the early and late transition. Boxes 1049 
indicate SUSD2+ and SUSD2- cell populations that were sorted. b) Plot showing the % 1050 
methylation in primed, early transition and late transition hESCs, for SUSD2+ and SUSD2- 1051 
cell populations. Each dot represents the methylation % of single CpGs (n = 57) from 4 1052 
genomic regions analysed by targeted bisulfite sequencing, and the red bars represent the 1053 
mean methylation level for each sample. Statistical difference between samples was 1054 
analysed by a Kruskal-Wallis test, with Dunn’s multiple comparisons post-hoc test. N.S. 1055 
denotes not significant (p > 0.05). c) qRT-PCR for naïve pluripotency genes in SUSD2+ and 1056 
SUSD2- cell populations early and late transition hESCs. Bars represent the mean of three 1057 
technical replicates and error bars represent SEM. Statistical significance between samples 1058 
was analysed with a one-way ANOVA with a Bonferroni post-hoc test comparing all samples 1059 
to each other. Human GAPDH was used to normalise expression. *P<0.05, **P<0.01, 1060 
***P<0.001, ****P<0.0001, N.S. denotes not significant. Source data are provided as a 1061 
Source Data file. 1062 
 1063 
Figure 5. Bivalent CGIs that lose H3K4me3 gain DNA methylation. a) Pie chart showing the 1064 
proportion of bivalent sites that do and do not gain methylation in naïve hESCs, and gene 1065 
ontology analysis of these bivalent hypermethylated and non-hypermethylated genes 1066 
respectively. b) ChIP-qPCR enrichment of H3K4me3 and c) H3K27me3 are shown for 6 1067 
candidate bivalent regions (possessing both H3K4me3 and H3K27me3 histone modifications 1068 
in primed cells) that become hypermethylated, and for 3 candidate bivalent regions that fail 1069 
to become hypermethylated during resetting (bottom row). Data is show as the signal 1070 
enrichment relative to the input sample with bars representing the mean of 2 independent 1071 
experiments. Statistical difference between samples was analysed by a one-way ANOVA 1072 
test, with Bonferroni post-hoc test of each time point compared to primed hESC. * indicates 1073 
p<0.05. Source data are provided as a Source Data file. 1074 
 1075 
Figure 6. Transcription and pluripotency factors influence hypermethylation. a) A selection 1076 
of the transcription factors with motifs enriched in bivalent hypermethylated regions, with 1077 
bivalent non-hypermethylated regions used as a background control. Motif analysis was 1078 
performed using the analysis of motif enrichment (AME) tool on the MEME suite.  b) 1079 
Volcano plots showing the difference in protein expression in early transition (72h and 1W) 1080 
hESCs compared to primed hESCs (Supplementary Table 6). Each dot represents the log2 1081 
fold change based on three biological replicates. Statistical difference between samples was 1082 
analysed by a two-tailed student’s t-test, corrected for multiple testing. Red dots indicate 1083 
statistically significant changes (adjP < 0.05). Proteins of interest are highlighted with 1084 
coloured and labelled symbols. c) Plot showing the % methylation for 4 different 1085 
transcription factor knock downs and a non-silencing control. Data for each sample are an 1086 
average of 2 independent shRNA knock downs. Each dot represents the methylation % of a 1087 
single CpG analysed by targeted bisulfite sequencing, and the red lines represent the mean 1088 
% methylation level for each sample from 5 genomic regions (SOX15 targets; n = 64 CpGs), 1089 
or 4 genomic regions (NFKB1 regions; n = 67 CpGs, or regions without TF binding sites for 1090 
any of the 4 TFs; n = 66 CpGs). Statistical difference between samples was analysed by a 1091 
two-way ANOVA test, with Bonferroni post-hoc test of each TF knock down compared to the 1092 
control. *P<0.05, **P<0.01, and ***P<0.001, ****P<0.0001. N.S. denotes not significant. d) 1093 
Targeted bisulfite-sequencing of 3 genomic regions. Each square represents the methylation 1094 
% indicated by the colour key of a single CpG. The first column represents data from primed 1095 
hESCs, and the subsequent columns represent data from early transition hESCs cultured in a 1096 
variety of culture conditions indicated by the +/- symbols above. Source data are provided 1097 
as a Source Data file. 1098 
 1099 
Figure 7. Resetting-associated hypermethylation is mirrored in cancer. a) Differences in 1100 
mean methylation level between matched normal tissue and tumour samples of bivalent 1101 
CpGs identified as hypermethylated (N=23123) or not hypermethylated (N=25977) during 1102 
the transition to the naïve state in hESCs. Data is presented for 592 individuals, separated by 1103 
tumour location. P-values determined via paired Wilcoxon test (two-sided). CpGs used for 1104 
analysis were filtered for those that are unmethylated in primed hESCs (β < 0.3). 1105 
Lines=median; Box=25th–75th percentile; whiskers=1.5× interquartile range from box. b) 1106 
Overlap of CpGs hypermethylated in cancers with bivalent CpGs hypermethylated during 1107 
hESC resetting. Values for all cancers were generated by testing all cancer samples against 1108 
all normal samples. P-values are determined using Fisher’s exact tests (two-sided). c) 1109 
Heatmap of H3K27me3 distribution in 250bp windows around each hESC Hypermethylated 1110 
CpG in normal colon (N=26180), ordered by total H3K27me3 reads within 5kb. Peaks are 1111 
taken from ENCODE (Supplementary Table 8). Scale is in normalised reads per million. d) 1112 
Selected genomic regions containing hESC Hypermethylated CpGs marked by H3K27me3 in 1113 
the normal colon (highlighted light orange). Mean methylation in normal colon and 1114 
colorectal tumours from TCGA, as well as the difference between them are shown in black. 1115 
hESC Hypermethylated CpGs are shown in blue, and H3K27me3 ChIP reads from ENCODE 1116 
are shown in orange (Supplementary Table 8). Scale for methylation data is 0 to 100%. Scale 1117 
for methylation difference is -50% to 50%. Scale for H3K27me3 is 0 to 30 normalised reads 1118 
per million reads.  1119 
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